Press Releases Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.51 ^USD	+0.67%		+2.03%	-21.76%

Apr. 23	Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	MT
Apr. 23	Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting	Apr. 25	AQ
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	Apr. 23	AQ
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	Apr. 15	AQ
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss	Feb. 06	AQ
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME	Dec. 12	AQ
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates	Nov. 13	AQ
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds	Nov. 10	AQ
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration	23-09-27	AQ
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates	23-08-08	AQ
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)	23-06-21	AQ
UNITY BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition (form 8-K)	23-05-09	AQ
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates	23-05-09	AQ
UNITY BIOTECHNOLOGY, INC. Change in Directors or Principal Officers (form 8-K/A)	23-04-28	AQ
UNITY BIOTECHNOLOGY, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-04-24	AQ
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema	23-04-24	AQ
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema	23-04-23	AQ
UNITY BIOTECHNOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)	23-04-11	AQ
Unity Biotechnology : Phase 2 ENVISION Program Update Call Presentation	23-03-27	PU
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration	23-03-27	AQ
UNITY Biotechnology : Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration - Form 8-K	23-03-27	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Press Releases

Filters